Global Breast Cancer Academy

Sharing Best Practices to Optimize Patient Care in Europe

Overview

In recent years, rapid advancements in treatment options for HR+ BC have transformed care paradigms. Innovations in targeted therapies, endocrine therapy, and improved understanding of biomarkers and resistance mechanisms have opened new paths for tailored patient care.

To address the evolving complexity in BC treatment, Aptitude Health established the Global Breast Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.

Date and Location

November 25, 2025; Virtual Meeting

Chair

Nadia Harbeck

Nadia Harbeck, MD, PhD

Ludwig-Maximilian University of Munich, Germany

Faculty

Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD

European Institute of Oncology, University of Milan, Italy

Joseph Gligorov

Joseph Gligorov, MD, PhD

Sorbonne University and Tenon Hospital (AP-HP), Paris, France

Peter Schmid

Peter Schmid, MD, PhD

St Bartholomew’s Hospital, London, England

Agenda

This interactive virtual meeting with global experts will focus on the treatment of patients with breast cancer in countries in Europe.

In recent years, rapid advancements in treatment options for HR+BC have transformed care paradigms. Innovations in targeted therapies, endocrine therapy, and improved understanding of biomarkers and resistance mechanisms have opened new paths for tailored patient care.

To address the evolving complexity in BC treatment, Aptitude Health established the Global Breast Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.

Virtual Plenary Sessions
Tuesday, November 25, 2025
17.30 – 20.30 (UTC+1) Paris

Time Topic Speaker
17.30 – 17.40 Welcome and meeting overview; introduction to the voting system Nadia Harbeck
Advancing Treatment Strategies in HR+, HER2+ BC: Disease Course Starting From Diagnosis
17.40 – 18.00

Initial therapy of HR+, HER2+ eBC – where to start and where to go

  • From diagnosis through perioperative therapy – neoadjuvant and adjuvant therapy decisions
  • Role of pCR and biomarkers in guiding post-resection therapy decisions – identification of high-risk patients who should consider extended adjuvant therapy
Peter Schmid
18.00 – 18.20

Monitoring and managing the treatment of patients post-resection

  • Monitoring – what (disease recurrence and the 3 As: AEs, adherence, attitude), where, and when?
  • How long is long enough? Extended adjuvant therapy decisions and discussions
Giuseppe Curigliano
18.20 – 19.00

BC case-based panel discussion

  • Case 1: HR+, HER2+ newly diagnosed eBC
  • Case 2: High-risk HR+, HER2+ BC – duration and adjuvant therapy selection (ET ± CDK4/6 inhibitor – 2 years? 3 years?)
  • Case 3: HR+, HER2+ recurrent disease
  • Q&A
Moderated by Nadia Harbeck
19.00 – 19.05 Break  
How Does HR+, HER2– mBC Treatment Look Today and Tomorrow?
19.05 – 19.35

Beyond a cure: Management of initial progression on ET

  • Roles of biomarkers, disease site, molecular profiling, and resistance mechanisms in guiding treatment decisions
  • Evolution of 1L treatment (eg, all patients need ET + CDK4/6 inhibitor? PI3K inhibitor + palbociclib + fulvestrant to which patients?)
  • ESR1 mutations – molecular progression vs disease progression?
Joseph Gligorov
19.35 – 19.50

Beyond ET: Endocrine therapy-resistant mBC

  • Biomarker-driven decisions – role of targeted therapies such as oral SERDs (eg, elacestrant), PI3K inhibitors (eg, alpelisib), mTOR inhibitors (eg, everolimus), AKT inhibitors (eg, capivasertib)
Giuseppe Curigliano
19.50 – 20.10

Panel discussion: What is the optimal sequencing strategy for HR+, HER2– mBC?

  • How to use serial endocrine approaches
  • ADCs
  • When to transition to chemotherapy
Nadia Harbeck and all faculty
20.10 – 20.20

How bright is the future of HR+ BC? Ongoing and planned clinical trials

  • Ongoing clinical trials and novel therapeutic strategies
Peter Schmid
20.20 –
20.30
Session close Nadia Harbeck